Compared to patients with private insurance, patients with Medicaid and Medicare coverage had higher in-hospital mortality rates after receiving CAR T-cell therapy, according to an abstract presented at the American Society of Clinical Oncology’s 2026 annual meeting.
Researchers from Valhalla, N.Y.-based New York Medical College and New Brunswick, N.J.-based Rutgers University analyzed National Inpatient Sample data of 10,610 CAR-T therapy hospitalizations between 2020 to 2022 for the study, according to a June 12 news release from the American Journal of Managed Care.
Here are three things to know from the study:
- The overall in-hospital mortality rate was 8.6%.
The in-hospital mortality rate for privately insured patients was 5.5%, while the rate for patients with Medicaid and Medicare was 10.7% and 11.5%, respectively. - The mortality ratio between Medicare patients and privately insured patients increased from 1.9 times higher in 2020 to 2.2 times higher in 2022.
- Researchers also found racial disparities among patients receiving CAR-T therapy, with Black and Hispanic patients receiving the therapy at about 67% and 72% of their expected rates, respectively.
Read the full study here.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
